Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Guoqin Zhai"'
Autor:
Douglas D. Fang, Ran Tao, Guangfeng Wang, Yuanbao Li, Kaixiang Zhang, Chunhua Xu, Guoqin Zhai, Qixin Wang, Jingwen Wang, Chunyang Tang, Ping Min, Dengkun Xiong, Jianyong Chen, Shaomeng Wang, Dajun Yang, Yifan Zhai
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-15 (2022)
Abstract Background Tyrosine kinase inhibitors (TKIs) are mainstays of cancer treatment. However, their clinical benefits are often constrained by acquired resistance. To overcome such outcomes, we have rationally engineered APG-2449 as a novel multi
Externí odkaz:
https://doaj.org/article/1dd21e343843436b9e179e454cd45d0c
Publikováno v:
PLoS ONE, Vol 6, Iss 9, p e25176 (2011)
BACKGROUND: N-ethyl-N-nitrosourea (ENU)-induced mutagenesis is a powerful tool for the study of gene function and the generation of human disease models. A large number of mouse mutants obtained by ENU-induced mutagenesis with a variety of phenotypes
Externí odkaz:
https://doaj.org/article/dd04cd38472c43999cc269fe13c878f9
Autor:
Douglas D. Fang, Qiuqiong Tang, Qixin Wang, Na Li, Feng Zhou, Guoqin Zhai, Yan Yin, Dajun Yang, Yifan Zhai
Publikováno v:
Molecular Cancer Therapeutics. 20:P208-P208
Background: In many hematologic malignancies, BCL-2 is overexpressed and is a viable therapeutic target. In relapsed or refractory acute myeloid leukemia (R/R AML), BCL-2 inhibitor venetoclax as a single agent has limited activity, thereby necessitat
Autor:
Yifan Zhai, Douglas D. Fang, Jiaxing Gu, Yan Yin, Guoqin Zhai, Xiaojing Huang, Ran Tao, Jing Deng, Dajun Yang, Kaixiang Zhang, Tingting Mao
Publikováno v:
Cancer Research. 80:74-74
Background: Gastric cancer is one of the most prevalent cancers in the East Asia population. The five-year survival rate is approximately 20% globally. The analysis of gene expression data suggests that anti-apoptotic protein BCL-xL may be the oncoge
Autor:
Danyi Wen, Yangfeng Ge, Ran Tao, Yifan Zhai, Miaoyi Wu, Yuanbao Li, Guangfeng Wang, Dajun Yang, Feifei Zhang, Jing Lv, Guoqin Zhai, Douglas D. Fang
Publikováno v:
Cancer Research. 80:6223-6223
Osimertinib (AZD9291) is the first-line treatment for EGFR-mutated NSCLC; however, the majority of patients inevitably develop resistance due to de novo genomic abnormalities, such as C797S mutation, EGFR exon 20 insertion, MET amplification and othe
Autor:
Guoqin Zhai, Qingyang Gu, Dajun Yang, Chunhua Xu, Zhu Saijie, Douglas D. Fang, Yifan Zhai, Jingwen Wang
Publikováno v:
Cancer Research. 79:1253-1253
Liposarcoma is a rare but highly recurrent soft tissue neoplasm. Combination of surgery and radiotherapy is the main treatment for liposarcoma patients while chemotherapy remains experimental and limited depends on disease subtypes. Well-differentiat
Autor:
Douglas D. Fang, Yifan Zhai, Guoqin Zhai, Xiaojing Huang, Tingting Mao, Dajun Yang, Yan Yin, Jing Deng
Publikováno v:
Cancer Research. 79:2503-2503
Background: BCL-2, an anti-apoptotic protein and oncogene, has been considered one of the top 10 targets for cancer drug development. The inhibition of BCL-2 and other anti-apoptotic proteins will help to restore the apoptotic pathway. Aiming to targ
Autor:
Guangfeng Wang, Ping Min, Ran Tao, Qixin Wang, Jiaxing Gu, Guoqin Zhai, Dingxiong Chen, Dongmei Yang, Yinfeng Li, Qiuqiong Tang, Shoulai Gu, Yifan Zhai, Jiajun Li, Douglas D. Fang, Dajun Yang
Publikováno v:
Cancer Research. 79:2058-2058
Follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) are among the most prevalent B-lymphocyte neoplasms with Bruton’s tyrosine kinase (BTK) often found abnormally activated in these patients. BTK inhibitor ibrutinib has showed proven
Autor:
Shoulai Gu, Xu Fang, Qiuqiong Tang, Guoqin Zhai, Qixin Wang, Yifan Zhai, Na Li, Jiajun Li, Ran Tao, Douglas D. Fang, Dajun Yang
Publikováno v:
Cancer Research. 79:3068-3068
Effective treatments are urgently needed for elderly acute myeloid leukemia (AML) and relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients as only 10-25% of the population respond to standard therapies and resistance often occurred.
Autor:
Fang Douglas Dong, Guoqin Zhai, Tingting Mao, Jing Deng, Shaomeng Wang, Dongmei Yang, Yan Yin, Yang Dajun, Yifan Zhai
Publikováno v:
Blood. 132:2616-2616
Introduction Evading apoptosis is one of the key mechanisms that cells become cancerous. Oncogenic proteins in the family, including BCL-2, BCL-xL, and MCL-1, which counteract the pro-death function of tumor suppressor like proteins, have been shown